# Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study

> **NCT07108530** · PHASE2 · RECRUITING · sponsor: **Shanxi Bethune Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** Integrated IAV/MA Chemotherapy and Allo-HSCT Protocol for Adult AML
- **DRUG:** First Induction (IAV or DAV Regimen)
- **DRUG:** Consolidation Therapy Options: MA or Intermediate-Dose Cytarabine Regimen
- **OTHER:** Subsequent Treatment Plan for Transplant-Eligible Patients
- **OTHER:** Allogeneic Stem Cell Transplantation Protocol
- **OTHER:** GVHD Prophylaxis Regimen
- **OTHER:** Subsequent Consolidation Therapy for Transplant-Ineligible Patients

## Key facts

- **NCT ID:** NCT07108530
- **Lead sponsor:** Shanxi Bethune Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2027-08-06
- **Final completion:** 2027-08-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108530, "Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07108530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*